Dr. Essell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4725 E Galbraith Rd
Ste 320
Blue Ash, OH 45236Phone+1 513-751-2273Fax+1 513-751-1840
Education & Training
San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1988 - 1991- San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1985 - 1988
University of Cincinnati College of MedicineClass of 1985
Certifications & Licensure
OH State Medical License 1981 - 2027
KY State Medical License 1997 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Top MD Consumers Checkbook
Clinical Trials
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2006 Jun 01
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
- Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
- Join now to see all
Publications & Presentations
PubMed
- 78 citationsROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.Madan Jagasia, Aleksandr Lazaryan, Carlos Bachier, Amandeep Salhotra, Daniel J. Weisdorf
Journal of Clinical Oncology. 2021-04-20 - 80 citationsLisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transpla...Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani
The Lancet. Oncology. 2022-08-01 - 121 citationsCommunity-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma RegimensRuben Niesvizky, Ian W. Flinn, Robert M. Rifkin, Nashat Y. Gabrail, Veena Charu
Journal of Clinical Oncology. 2015-06-08
Press Mentions
Canopy Launches Platform-Wide Support for Bispecific AntibodiesSeptember 25th, 2024- OHC and Jewish Hospital 1st in Region to Offer Revolutionary Cancer Treatment for Multiple MyelomaAugust 13th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
